Clinical characteristics, one-year change in ejection fraction and long-term outcomes in patients with heart failure with mid-range ejection fraction: a multicentre prospective observational study in Catalonia (Spain)
Por:
Farre, N, Lupon, J, Roig, E, Gonzalez-Costello, J, Vila, J, Perez, S, de Antonio, M, Sole-Gonzalez, E, Sanchez-Enrique, C, Moliner, P, Ruiz, S, Enjuanes, C, Mirabet, S, Bayes-Genis, A and Comin-Colet, J
Publicada:
1 dic 2017
Categoría:
Medicine (miscellaneous)
Resumen:
Objectives The aim of this study was to analyse baseline characteristics and outcome of patients with heart failure and mid-range left ventricular ejection fraction (HFmrEF, left ventricular ejection fraction (LVEF) 40%-49%) and the effect of 1-year change in LVEF in this group.
Setting Multicentre prospective observational study of ambulatory patients with HF followed up at four university hospitals with dedicated HF units.
Participants Fourteen per cent (n=504) of the 3580 patients included had HFmrEF.
Interventions Baseline characteristics, 1-year LVEF and outcomes were collected. All-cause death, HF hospitalisation and the composite end-point were the primary outcomes.
Results Median follow-up was 3.66 (1.69-6.04) years. All-cause death, HF hospitalisation and the composite end-point were 47%, 35% and 59%, respectively. Outcomes were worse in HF with preserved ejection fraction (HFpEF) (LVEF>50%), without differences between HF with reduced ejection fraction (HFrEF) (LVEF<40%) and HFmrEF (all-cause mortality 52.6% vs 45.8% and 43.8%, respectively, P=0.001). After multivariable Cox regression analyses, no differences in all-cause death and the composite end-point were seen between the three groups. HF hospitalisation and cardiovascular death were not statistically different between patients with HFmrEF and HFrEF. At 1-year follow-up, 62% of patients with HFmrEF had LVEF measured: 24% had LVEF<40%, 43% maintained LVEF 40%-49% and 33% had LVEF>50%. While change in LVEF as continuous variable was not associated with better outcomes, those patients who evolved from HFmrEF to HFpEF did have a better outcome. Those who remained in the HFmrEF and HFrEF groups had higher all-cause mortality after adjustment for age, sex and baseline LVEF (HR 1.96 (95% CI 1.08 to 3.54, P=0.027) and HR 2.01 (95% CI 1.04 to 3.86, P=0.037), respectively).
Conclusions Patients with HFmrEF have a clinical profile in-between HFpEF and HFrEF, without differences in all-cause mortality and the composite end-point between the three groups. At 1 year, patients with HFmrEF exhibited the greatest variability in LVEF and this change was associated with survival.
Filiaciones:
Farre, N:
Hosp del Mar, Dept Cardiol, Heart Failure Unit, Barcelona, Spain
Hosp del Mar Med Res Inst IMIM, Heart Dis Biomed Res Grp GREC, Barcelona, Spain
Univ Autonoma Barcelona, Dept Med, Catalunya, Spain
:
Univ Autonoma Barcelona, Dept Med, Catalunya, Spain
Hosp Badalona Germans Trias & Pujol, Heart Failure Unit, Barcelona, Spain
CIBER Enfermedades Cardiovasc, CIBERCV, Barcelona, Spain
Roig, E:
Univ Autonoma Barcelona, Dept Med, Catalunya, Spain
CIBER Enfermedades Cardiovasc, CIBERCV, Barcelona, Spain
Hosp Santa Creu & Sant Pau, Heart Failure Unit, Barcelona, Spain
Gonzalez-Costello, J:
Hosp Univ Bellvitge, Heart Dis Inst, Barcelona, Spain
Hosp Llobregat, Bellvitge Biomed Reserach Inst, IDIBELL, Barcelona, Spain
Vila, J:
Hosp del Mar Med Res Inst IMIM, Cardiovasc Epidemiol & Genet EGEC,REGICOR Study G, Barcelona, Spain
CIBER Epidemiol & Salud Publ, CIBERESP, Barcelona, Spain
Perez, S:
CIBER Enfermedades Cardiovasc, CIBERCV, Barcelona, Spain
Hosp del Mar Med Res Inst IMIM, Cardiovasc Epidemiol & Genet EGEC,REGICOR Study G, Barcelona, Spain
:
Hosp Badalona Germans Trias & Pujol, Heart Failure Unit, Barcelona, Spain
Sole-Gonzalez, E:
Univ Autonoma Barcelona, Dept Med, Catalunya, Spain
CIBER Enfermedades Cardiovasc, CIBERCV, Barcelona, Spain
Hosp Santa Creu & Sant Pau, Heart Failure Unit, Barcelona, Spain
Sanchez-Enrique, C:
Hosp Univ Bellvitge, Heart Dis Inst, Barcelona, Spain
Hosp Llobregat, Bellvitge Biomed Reserach Inst, IDIBELL, Barcelona, Spain
:
Hosp Badalona Germans Trias & Pujol, Heart Failure Unit, Barcelona, Spain
Ruiz, S:
Hosp del Mar, Dept Cardiol, Heart Failure Unit, Barcelona, Spain
Hosp del Mar Med Res Inst IMIM, Heart Dis Biomed Res Grp GREC, Barcelona, Spain
Enjuanes, C:
Hosp del Mar Med Res Inst IMIM, Heart Dis Biomed Res Grp GREC, Barcelona, Spain
Hosp Univ Bellvitge, Heart Dis Inst, Barcelona, Spain
Hosp Llobregat, Bellvitge Biomed Reserach Inst, IDIBELL, Barcelona, Spain
Univ Barcelona, Sch Med, Dept Clin Sci, Badalona, Spain
Mirabet, S:
Univ Autonoma Barcelona, Dept Med, Catalunya, Spain
CIBER Enfermedades Cardiovasc, CIBERCV, Barcelona, Spain
Hosp Santa Creu & Sant Pau, Heart Failure Unit, Barcelona, Spain
:
Univ Autonoma Barcelona, Dept Med, Catalunya, Spain
Hosp Badalona Germans Trias & Pujol, Heart Failure Unit, Barcelona, Spain
CIBER Enfermedades Cardiovasc, CIBERCV, Barcelona, Spain
Comin-Colet, J:
Hosp del Mar Med Res Inst IMIM, Heart Dis Biomed Res Grp GREC, Barcelona, Spain
Hosp Univ Bellvitge, Heart Dis Inst, Barcelona, Spain
Hosp Llobregat, Bellvitge Biomed Reserach Inst, IDIBELL, Barcelona, Spain
Univ Barcelona, Sch Med, Dept Clin Sci, Badalona, Spain
gold, Green Published
|